Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have been assigned an average rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $28.83.

A number of brokerages have issued reports on IMNM. Stephens assumed coverage on Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price for the company. Piper Sandler dropped their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Finally, Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Immunome in a report on Monday.

Insider Activity at Immunome

In other news, CEO Clay B. Siegall purchased 66,057 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were acquired at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the transaction, the chief executive officer now owns 485,693 shares of the company’s stock, valued at $4,633,511.22. The trade was a 15.74 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Philip Tsai acquired 21,000 shares of the stock in a transaction dated Thursday, November 21st. The stock was acquired at an average cost of $9.43 per share, with a total value of $198,030.00. Following the completion of the transaction, the chief technology officer now owns 21,000 shares in the company, valued at approximately $198,030. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 102,862 shares of company stock worth $978,045 over the last ninety days. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

A number of institutional investors and hedge funds have recently modified their holdings of the business. Marshall Wace LLP boosted its stake in Immunome by 228.5% during the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after acquiring an additional 1,191,774 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Immunome by 217.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after buying an additional 302,916 shares in the last quarter. Victory Capital Management Inc. increased its position in Immunome by 48.1% in the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after buying an additional 237,497 shares in the last quarter. Finally, AXA S.A. bought a new position in Immunome in the second quarter worth approximately $2,174,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Performance

NASDAQ IMNM opened at $9.38 on Wednesday. Immunome has a fifty-two week low of $8.97 and a fifty-two week high of $30.96. The stock has a market cap of $585.47 million, a PE ratio of -1.16 and a beta of 1.90. The firm’s fifty day moving average price is $11.72 and its two-hundred day moving average price is $12.98.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.